Study illuminates tiny RNA’s role in heart disease, obesity
A tiny RNA molecule plays a big role in the development of two diseases affecting billions of people worldwide: heart disease and obesity. Yale researchers have found that by disrupting this microRNA in key tissues, they can reduce plaque buildup in arteries while avoiding unintended effects.
Yale lab finding may protect the heart during ischemia
Research from three Yale laboratories — in the fields of immunobiology, chemistry, and cardiology — could lead to new drugs to reduce complications during cardiac surgery or heart attacks. If they pan out in human trials, the drugs would limit the detrimental impact of ischemia—restriction of blood flow—thereby cutting the degree of damage to the heart. The research appeared in the June online issue of Circulation.
Outcomes Similar After TAVR in Bicuspid, Tricuspid Anatomy
All-cause mortality and stroke are comparable at 30 days and one year after transcatheter aortic valve replacement (TAVR) among patients with bicuspid and tricuspid valve stenosis, according to a study published online May 27 in JACC: Cardiovascular Interventions.Source: HealthDay
Coronavirus infection may cause lasting damage throughout the body, doctors fear
For a world grappling with the new coronavirus, it’s becoming increasingly clear that even when the pandemic is over, it won’t really be over. Now doctors are beginning to worry that for patients who have survived COVID-19, the same may be true.Source: Los Angeles Times
Opinion: Hydroxychloroquine And Azithromycin For COVID-19: Benefits TBD, Risks Clear
In the midst of a pandemic, lots of people have ideas for cures. We are desperate for therapies and the virus can be deadly. The problem is that the presumptive cure can add danger to the disease, rather than mitigate it.Source: Forbes
Long Term Results Favor CABG—Is This Surprising?
Ever since the first interventional cardiologist threaded a catheter into an occluded artery in the heart and inflated a balloon to widen the narrowed artery, a turf war has ebbed and flowed between interventionalists and surgeons over the best way to treat CAD.Source: Physicians Weekly
Registry data show lower event rates vs. trial data for LAA closure device
Patients with atrial fibrillation who underwent left atrial appendage occlusion with an FDA-approved device had lower rates of major in-hospital adverse events compared with previous trials assessing the device.Source: Healio